Mirum Pharmaceuticals, Inc. (MIRM) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Mirum Pharmaceuticals reported revenue of $521.3M, up 54.7% from $336.9M the year before. Net income was -$23.4M (a -4.5% net margin), or -$0.47 per diluted share. Operating margin was -4.2%. Operating activities generated $55.8M of cash, leaving $54.9M of free cash flow. At fiscal year end, Mirum Pharmaceuticals held $842.8M in total assets against $528.1M in total liabilities, including $296.7M of cash and equivalents.
Open the full interactive Mirum Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Mirum Pharmaceuticals Key Stats
| Share Price | $79.62 |
|---|---|
| Market Cap | $5.05B |
| Revenue YoY Growth | +54.7% |
| 52-Week Range | $64.10 – $128.57 |
| Shares Outstanding | 63.4 million (basic, 2026 Q2) |
Mirum Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $19.1M | $77.1M | $186.4M | $336.9M | $521.3M |
| Operating Income | -$104.3M | -$173.4M | -$131.2M | -$109.2M | -$87.6M | -$22.1M |
| Pre-Tax Income | -$103.3M | -$84.0M | -$142.1M | -$162.4M | -$86.9M | -$21.4M |
| Income Tax | $6,000 | $37,000 | -$6.4M | $991,000 | $1.0M | $1.9M |
| Net Income | -$103.3M | -$84.0M | -$135.7M | -$163.4M | -$87.9M | -$23.4M |
| Diluted EPS | -$4.09 | -$2.77 | -$4.02 | -$4.00 | -$1.85 | -$0.47 |
Mirum Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $133.0M | $148.9M | $159.9M | $176.2M |
| Net Income | $2.9M | -$5.7M | -$790.2M | -$67.2M |
| Diluted EPS | $0.05 | -$0.11 | -$13.43 | -$1.06 |
Mirum Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $142.1M | $31.3M | $28.0M | $286.3M | $222.5M | $296.7M |
| Current Assets | $236.3M | $166.6M | $190.2M | $387.5M | $392.8M | $549.7M |
| Total Assets | $240.9M | $294.7M | $352.9M | $646.6M | $670.8M | $842.8M |
| Current Liabilities | $18.5M | $42.6M | $64.7M | $87.1M | $126.6M | $205.8M |
| Total Long-Term Debt | — | — | — | $306.4M | $308.1M | $309.8M |
| Total Liabilities | $68.8M | $174.4M | $210.9M | $398.0M | $445.1M | $528.1M |
| Shareholders' Equity | $172.1M | $120.2M | $142.0M | $248.7M | $225.6M | $314.7M |
Mirum Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$89.1M | -$132.8M | -$120.1M | -$70.9M | $10.3M | $55.8M |
| Cash From Investing | $37.9M | $48.5M | $7.7M | -$107.2M | -$90.1M | -$24.0M |
| Cash From Financing | $181.3M | $73.5M | $109.1M | $336.6M | $17.7M | $40.1M |
| Free Cash Flow | -$89.3M | -$132.8M | -$120.4M | -$71.1M | $9.3M | $54.9M |
Figures from Mirum Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Mirum Pharmaceuticals financials page for every line item.
Mirum Pharmaceuticals Company Profile
| Ticker | MIRM |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Foster City, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001759425 |
Frequently Asked Questions
What was Mirum Pharmaceuticals' revenue in fiscal 2025?
Mirum Pharmaceuticals (MIRM) reported revenue of $521.3M for fiscal 2025.
What is Mirum Pharmaceuticals' annual revenue history?
Mirum Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $19.1M; 2022: $77.1M; 2023: $186.4M; 2024: $336.9M; 2025: $521.3M.
What was Mirum Pharmaceuticals' net income in fiscal 2025?
Mirum Pharmaceuticals reported net income of -$23.4M for fiscal 2025.
What was Mirum Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Mirum Pharmaceuticals' diluted EPS was -$0.47 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Mirum Pharmaceuticals generate in fiscal 2025?
Mirum Pharmaceuticals generated $54.9M of free cash flow in fiscal 2025.
What was Mirum Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Mirum Pharmaceuticals reported revenue of $176.2M.
How much debt does Mirum Pharmaceuticals have?
Mirum Pharmaceuticals reported $309.8M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Mirum Pharmaceuticals are outstanding?
Mirum Pharmaceuticals reported a weighted average of 63.4 million basic shares outstanding in 2026 Q2.
What is Mirum Pharmaceuticals' market cap?
Based on its latest closing price, Mirum Pharmaceuticals (MIRM) has a market capitalization of about $5.05B.
When does Mirum Pharmaceuticals' fiscal year end?
Mirum Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Mirum Pharmaceuticals headquartered?
Mirum Pharmaceuticals lists its business address in Foster City, California in its SEC filings.